Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin C studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -11% Improvement Relative Risk Vitamin C for COVID-19  Li et al.  ICU PATIENTS Is very late treatment with vitamin C beneficial for COVID-19? PSM retrospective 32 patients in the USA No significant difference in mortality c19early.org Li et al., J. Pharmacy Practice, June 2021 Favors vitamin C Favors control

Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection

Li et al., Journal of Pharmacy Practice, doi:10.1177/08971900211015052
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin C for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.000000087 from 70 studies, recognized in 11 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
PSM retrospective 8 ICU patients treated with vitamin C and 24 matched controls, showing no significant difference. Authors note that "it is possible for the delayed timing of IV vitamin C to have blunted the beneficial effects as these patients may have already progressed to the late fibroproliferative phase or ARDS". IV vitamin C 1.5 grams every 6 hours.
This is the 28th of 70 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.000000087 (1 in 11 million).
21 studies are RCTs, which show efficacy with p=0.0012.
This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients; very late stage, ICU patients.
risk of death, 10.5% higher, RR 1.11, p = 1.00, treatment 7 of 8 (87.5%), control 19 of 24 (79.2%), PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 8 Jun 2021, retrospective, propensity score matching, USA, peer-reviewed, 6 authors.
This PaperVitamin CAll
Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection
PharmD, BCPS, BCCCP Matthew Li, MD Tsung Han Ching, MIDS Christopher Hipple, MD Ricardo Lopez, MD Asad Sahibzada, MD Habibur Rahman
Journal of Pharmacy Practice, doi:10.1177/08971900211015052
Introduction: The pathophysiology for Coronavirus Disease 2019 (COVID-19) infection is characterized by cytokine oxidative stress and endothelial dysfunction. Intravenous (IV) vitamin C has been utilized as adjuvant therapy in critically ill patients with sepsis for its protective effects against reactive oxygen species and immunomodulatory effects. The primary objective of this study was to evaluate the effects of IV vitamin C in critically ill patients with COVID-19 infection. Methods: Retrospective observational cohort study with propensity score matching of intensive care unit (ICU) patients who received 1.5 grams IV vitamin C every 6 hours for up to 4 days for COVID-19 infection. The primary study outcome was in-hospital mortality. Secondary outcomes included vasopressor requirements in norepinephrine equivalents, ICU length of stay, and change in Sequential Organ Failure Assessment (SOFA) score. Results: Eight patients received IV vitamin C and were matched to 24 patients. Patients in the IV vitamin C group had higher rates of hospital mortality [7 (88%) vs. 19 (79%), P ¼ 0.049]. There was no difference in the daily vasopressor requirement in the treatment group or between the 2 groups. The mean SOFA scores post-treatment was higher in the IV vitamin C group (12.4 + 2.8 vs. 8.1 + 3.5, P < 0.005). There was no difference in ICU length of stay between the treatment and control groups. Conclusion: Adjunctive IV vitamin C for the management of COVID-19 infection in critically ill patients may not decrease the incidence of mortality, vasopressor requirements, SOFA scores, or ventilator settings.
ORCID iD Matthew Li, PharmD, BCPS, BCCCP https://orcid.org/0000-0003-1320-7134
References
Annane, Adrenal insufficiency in sepsis, Curr Pharm Des, doi:10.2174/138161208784980626
Ascor, None
Bharara, Grossman, Grinnan, Intravenous vitamin C administered as adjunctive therapy for recurrent acute respiratory distress syndrome, Case Rep Crit Care, doi:10.1155/2016/8560871
Boretti, Banik, Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome, Pharma-Nutrition, doi:10.1016/j.phanu.2020.100190
Carr, Maggini, Vitamin C and immune function, Nutrients, doi:10.3390/nu9111211
Carr, Wohlrab, Young, Stability of intravenous vitamin C solutions: a technical report, Crit Care Resusc
Castelli, Cimini, Ferri, Cytokine storm in COVID-19: "When you come out of the storm, you won't be the same person who walked in, Front Immunol, doi:10.3389/fimmu.2020.02132
Corrao, Use of Ascorbic Acid in Patients with COVID 19
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, doi:10.1016/S0140-6736(20)31189-2
Delgado-Roche, Mesta, Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection, Arch Med Res, doi:10.1016/j.arcmed.2020.04.019
Fowler, Iii, Truwit, Hite, Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial, JAMA, doi:10.1001/jama.2019.11825
Fujii, Luethi, Young, Effect of vitamin C, hydrocortisone, and thiamine versus hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the vitamins randomized clinical trial, JAMA, doi:10.1001/jama.2019.22176
Gavriilaki, Anyfanti, Gavriilaki, Endothelial dysfunction in COVID-19: lessons learned from coronaviruses, Curr Hypertens Rep, doi:10.1007/s11906-020-01078-6
Gupta, Wang, Hayek, Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19, JAMA Intern Med, doi:10.1001/jamainternmed.2020.6252
Hermine, Tharaux, Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial, JAMA Intern Med, doi:10.1001/jamain-ternmed.2020.6820
Hiedra, Lo, Elbashabsheh, The use of IV vitamin C for patients with COVID-19: a case series, Expert Rev Anti Infect Ther, doi:10.1080/14787210.2020.1794819
Hoang, Shaw, Fang, Possible application of highdose vitamin C in the prevention and therapy of coronavirus infection, J Glob Antimicrob Resist, doi:10.1016/j.jgar.2020.09.025
Horby, Pessoa-Amorim, Peto, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomized, controlled, open-label, platform trial, medRxiv, doi:10.1101/2021.02.11.21249258
Kouakanou, Xu, Peters, Vitamin C promotes the proliferation and effector functions of human gd T cells, Cell Mol Immunol, doi:10.1038/s41423-019-0247-8
Lamontagne, Lessening Organ Dysfunction with Vitamin C-COVID-19 (LOVIT-COVID)
Liu, Zhu, Zhang, Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicenter randomized controlled trial, BMJ Open, doi:10.1136/bmjopen-2020-039519
Marik, Khangoora, Rivera, Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock, Chest, doi:10.1016/j.chest.2016.11.036
Moskowitz, Huang, Hou, Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial, JAMA, doi:10.1001/jama.2020.11946
Ragab, Salah Eldin, Taeimah, The COVID-19 cytokine storm; what we know so far, Front Immunol, doi:10.3389/fimmu.2020.01446
Russell, Walley, Singer, Vasopressin versus norepinephrine infusion in patients with septic shock, N Engl J Med, doi:10.1056/NEJMoa067373
Stone, Frigault, Boyd, Efficacy of tocilizumab in patients hospitalized with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2028836
Tsai, Diawara, Nahass, Impact of tocilizumab administration on mortality in severe COVID-19, Sci Re, doi:10.1038/s41598-020-76187-y
Wajanaponsan, Reade, Milbrandt, Steroids in late ARDS?, Crit Care, doi:10.1186/cc5954
Wilson, Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium, Biofactors, doi:10.1002/biof.7
Woolum, Abner, Kelly, Effect of thiamine administration on lactate clearance and mortality in patients with septic shock, Crit Care Med
Ye, Wang, Mao, The pathogenesis and treatment of the "Cytokine Storm" in COVID-19, J Infect, doi:10.1016/j.jinf.2020.03.037
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit